30 closest matches · ranked by relevance
Heparin-induced Thrombocytopenia Type II
Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Primary: Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II — 31; 4; 45; 78 participants
Heparin Induced Thrombocytopenia
Primary: Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis — 17.5; 27.8; 31.4 days — p=0.003
Thrombosis
Primary: Thrombosis — 8; 6 participants
Venous Thrombosis
Primary: Development of DVT (Deep Vein Thrombosis)
Traumatic Injury · Venous Thromboembolism
Primary: Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization — 87; 82 Percent AT-III activity (%) — p=0.092
Deep-Venous Thrombosis · Pulmonary Embolism · Venous Thromboembolism
Primary: Number of Participants With Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL) — 0; 12 Participants
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Venous Thromboembolism
Primary: To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels…
Recurrent Abortion
Primary: Live Birth Rate = (Number of Live Births / Total Number of Pregnancies) — 24; 20 Percentage of pregnancies
Sars-CoV2 · COVID
Primary: Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days. — 25; 31 Participants
Covid19
Primary: Change in Activated Partial Thromboplastin Time (APTT) > 1.5 Seconds — 0.95; 1.10 ratio
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
Acute ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion…
COVID 19 Associated Coagulopathy
Primary: Mortality — 18; 13 Participants
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Coronary Artery Disease
Primary: Major Adverse Cardiac Events — 2 percentage of event
Pregnancy Related · Antepartum DVT
Primary: Number of Participants With Elevated Serum Activated Partial Thromboplastin Time Above the Normal Range (> 36.2 Seconds). — 1; 8 Participants
Acute Coronary Syndromes
Primary: The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to…
Left Sided Heart Failure · Left Ventricular Assist Device · Anticoagulant Therapy
Primary: Nomogram Feasibility — 136; 112; 136; 111 Surveys — p=.45
Blood Loss, Surgical
Primary: Number or Participants With Antirecombinant Thrombin (rThrombin) Product Antibody at Baseline and Day 29 — 0; 0 Participants
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants
Coronary Artery Disease · Angina, Unstable
Primary: Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment. — 301.0; 330.0; 354.0; 237.5 second
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Heart Catheterization
Primary: Percentage of Participants Who Require Anticoagulation and/or Have Clinical Signs of Catheter Related Thrombosis — 10.5; 14.3; 10.0 Percentage of participants
Covid19
Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…
Immune Thrombocytopenic Purpura
Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Coronary Artery Disease
Primary: Chest Tube Losses — 726; 781 millilters — p=<0.1